FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)

View source ↗

Summary

The FDA approved a supplemental application for EYLEA HD (aflibercept) by Regeneron, introducing a high-dose formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• EYLEA HD (aflibercept)

Snippet

SUPPL AP for EYLEA HD (AFLIBERCEPT)